Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Chimerix Inc

CMRX
Current price
2.76 USD +0.58 USD (+26.61%)
Last closed 0.83 USD
ISIN US16934W1062
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 80 025 136 USD
Yield for 12 month +179.72 %
1Y
3Y
5Y
10Y
15Y
CMRX
21.11.2021 - 28.11.2021

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina. Address: 2505 Meridian Parkway, Durham, NC, United States, 27713

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7 USD

P/E ratio

Dividend Yield

Current Year

+324 000 USD

Last Year

+33 824 000 USD

Current Quarter

+26 000 USD

Last Quarter

+129 000 USD

Current Year

+324 000 USD

Last Year

+33 377 000 USD

Current Quarter

+26 000 USD

Last Quarter

+105 000 USD

Key Figures CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -92 735 000 USD
Operating Margin TTM -95357.7 %
PE Ratio
Return On Assets TTM -30.22 %
PEG Ratio
Return On Equity TTM -48.59 %
Wall Street Target Price 7 USD
Revenue TTM 159 000 USD
Book Value 1.51 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 136.4 %
Dividend Yield
Gross Profit TTM -36 486 000 USD
Earnings per share -0.94 USD
Diluted Eps TTM -0.94 USD
Most Recent Quarter III 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CMRX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CMRX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.2136
Enterprise Value Revenue 3.5749
Price Sales TTM 503.3027
Enterprise Value EBITDA 1.0307
Price Book MRQ 0.5894

Financials CMRX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CMRX

For 52 weeks

0.75 USD 1.3 USD
50 Day MA 0.91 USD
Shares Short Prior Month 1 518 700
200 Day MA 0.95 USD
Short Ratio 2.74
Shares Short 710 246
Short Percent 0.83 %